Differential inhibition of platelet function by cilostazol in combination with clopidogrel.
Cilostazol
Clopidogrel
Ischemic stroke
Platelet function tests
Vasodilator-stimulated phosphoprotein
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
31
01
2023
accepted:
13
08
2023
medline:
22
11
2023
pubmed:
23
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
To assess the antiplatelet effect of cilostazol clinically, we compared the effects of cilostazol in combination with clopidogrel on various platelet function tests. We recruited patients with ischemic stroke at high risk of recurrence who were treated with clopidogrel alone within 180 days after stroke onset. Subjects underwent baseline platelet function tests, and were then randomly assigned to receive dual antiplatelet therapy (DAPT) comprising clopidogrel and cilostazol or clopidogrel monotherapy (SAPT). After 6 months, platelet function was measured again and compared to that at baseline in each group, and the rate of change was compared between groups. Thirty-four patients were enrolled, but 4 patients were excluded for various reasons. In total, 30 subjects (13 in DAPT and 17 in SAPT group) were analyzed. Adenosine diphosphate- and collagen-induced aggregation, VerifyNow P2Y The inhibitory effects of adjunctive cilostazol added to clopidogrel on platelet function differed by type of platelet function test. VerifyNow % inhibition and PRI were more inhibited than the other platelet function tests. CSPS.com substudy in TWMU (UMIN000026672), registered on April 1, 2017. This study was performed as a substudy of CSPS.com (UMIN000012180, registered on October 31, 2013) and was retrospectively registered.
Identifiants
pubmed: 37740121
doi: 10.1007/s00228-023-03553-w
pii: 10.1007/s00228-023-03553-w
doi:
Substances chimiques
Clopidogrel
A74586SNO7
Cilostazol
N7Z035406B
Platelet Aggregation Inhibitors
0
Ticlopidine
OM90ZUW7M1
Aspirin
R16CO5Y76E
Tetrazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1623-1630Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Goto F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y (2000) Cilostazol stroke prevention study: A placebo controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9:147–157. https://doi.org/10.1053/jscd.2000.7216
doi: 10.1053/jscd.2000.7216
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, CSPS 2 group (2010) Cilostazol for prevention of secondary stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959–968. https://doi.org/10.1016/S1474-4422(10)70198-8
doi: 10.1016/S1474-4422(10)70198-8
Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, on behalf of the CSPS.com Trial Investigators (2019) Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 18:539–548. https://doi.org/10.1016/S1474-4422(19)30148-6
doi: 10.1016/S1474-4422(19)30148-6
Liu Y, Shakur Y, Yoshitake M, Kambayashi J (2001) Cilostazol (Pletal
doi: 10.1111/j.1527-3466.2001.tb00076.x
Inoue T, Sohma R, Morooka S (1999) Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93:137–143. https://doi.org/10.1016/S0049-3848(98)00172-8
doi: 10.1016/S0049-3848(98)00172-8
Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K (2001) Inhibition of platelet aggregation and the release of p-selectin from platelets by cilostazol. Thromb Res 101:445–453. https://doi.org/10.1016/S0049-3848(00)00415-1
doi: 10.1016/S0049-3848(00)00415-1
Yamamoto H, Takahashi K, Watanabe H, Yoshikawa Y, Shirakawa R, Higashi T, Kawato M, Ikeda T, Tabuchi A, Morimoto T, Kita T, Horiuchi H (2008) Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J 72:1844–1851. https://doi.org/10.1253/circj.CJ-08-0289
doi: 10.1253/circj.CJ-08-0289
Satoh K, Fukasawa I, Kanemaru K, Yoda S, Kimura Y, Inoue O, Ohta M, Kinouchi H, Ozaki Y (2012) Platelet aggregometry in the presence of PGE1 provides a reliable method for cilostazol monitoring. Thromb Res 130:616–621. https://doi.org/10.1016/j.thromres.2012.05.030
doi: 10.1016/j.thromres.2012.05.030
Yamanouchi J, Hato T, Niiya T, Nakagawa K, Kumon Y, Fujiwara H, Yakushijin Y, Yasukawa M (2011) Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol. Platelets 22:135–142. https://doi.org/10.3109/09537104.2010.525976
doi: 10.3109/09537104.2010.525976
Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U (2007) Specific impairment of human platelet P2Y(AC)ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Vasc Biol 7:249–52. https://doi.org/10.1161/01.atv.19.8.2007
Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ (2007) Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and p-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 100:610–614. https://doi.org/10.1016/j.amjcard.2007.03.070
doi: 10.1016/j.amjcard.2007.03.070
Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Bass GLA (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29:2202–2211. https://doi.org/10.1093/eurheartj/ehn287
doi: 10.1093/eurheartj/ehn287
Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW (2009) Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J Am Coll Cardiol 53:1101–1109. https://doi.org/10.1016/j.jacc.2008.12.025
doi: 10.1016/j.jacc.2008.12.025
Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T, for the CSPS.com Study Investigators (2015) Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke 10:253–258. https://doi.org/10.1111/ijs.12420
doi: 10.1111/ijs.12420
Yamazaki M, Uchiyama S, Iwata M (2001) Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 104:197–205. https://doi.org/10.1016/S0049-3848(01)00350-4
doi: 10.1016/S0049-3848(01)00350-4
Yamazaki M, Ohnishi T, Hosokawa K, Yamaguchi K, Yoneyama T, Kawashima A, Okada Y, Kitagawa K, Uchiyama S (2016) Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. J Thromb Haemost 14:1788–1797. https://doi.org/10.1111/jth.13391
doi: 10.1111/jth.13391
Fisher RG, Teitel ER, Yee AT, Chuang AZ (2013) Evaluation of the effectiveness of the AggreGuide A-100 in measuring platelet aggregation in individuals taking a high or low dose of aspirin. Lab Medicine 44:e83–e91. https://doi.org/10.1309/LMJF9WK85YAAAEYV
doi: 10.1309/LMJF9WK85YAAAEYV
Madhavi R, Rajasekhar D, Vanajakshamma V, Reddy GO, Kapil C, Sowjenya G (2018) Variability in antiplatelet drugs’ response in Indian patients undergoing percutaneous coronary intervention and outcome modification by tailored antiplatelet therapy. J Cardiol Cardiovasc Ther 9:555762. https://doi.org/10.19080/JOCCT.2018.09.555762
Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka K, Maruyama I (2012) A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 83:154–161. https://doi.org/10.1016/j.mvr.2011.11.007
doi: 10.1016/j.mvr.2011.11.007
Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I (2013) Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 109:102–111. https://doi.org/10.1160/TH12-06-0441
doi: 10.1160/TH12-06-0441
Maruyama H, Takeda H, Dembo T, Nagoya H, Kato Y, Fukuoka T, Deguchi I, Horiuchi Y, Tanahashi N (2011) Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic atroke or carotid artery stenting using the VerifyNow P2Y12 assay. Intern Med 50:695–698. https://doi.org/10.2169/internalmedicine.50.4623
doi: 10.2169/internalmedicine.50.4623
KhannaV HA, Mikael R, Sambu N, Englyst N, Curzen N (2014) Does the VerifyNow P2Y12 assay overestimate “therapeutic response” to clopidogrel? Insights using short thrombelastography Thromb Haemost 111:1150–1159. https://doi.org/10.1160/TH13-10-0856
doi: 10.1160/TH13-10-0856
Bieber M, Schuhmann MK, Volz J, Kumar GJ, Vaidya JR, Nieswandt B, Pham M, Stoll G, Kleinschnitz C, Kraft P (2019) Description of a novel phosphodiesterase (PDE)-3 Inhibitor protecting mice from ischemic stroke independent from platelet function. Stroke 50:478–486. https://doi.org/10.1161/STROKEAHA.118
doi: 10.1161/STROKEAHA.118